No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GPCR Structure Therapeutics
- 38.320
- +1.940+5.33%
Close May 23 16:00 ET
- 39.550
- +1.230+3.21%
Post 19:43 ET
1.79BMarket Cap-18291P/E (TTM)
40.000High36.410Low767.95KVolume37.610Open36.380Pre Close29.70MTurnover2.00%Turnover RatioLossP/E (Static)46.62MShares75.01752wk High4.16P/B1.47BFloat Cap25.57052wk Low--Dividend TTM38.40MShs Float75.017Historical High--Div YieldTTM9.87%Amplitude20.800Historical Low38.672Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Buy Rating on Structure Therapeutics' GSBR-1290 for Non-T2D Obesity Potential
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
The Structure Therapeutics (NASDAQ:GPCR) stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.What Happened: JPMorgan
J.P. Morgan Starts Structure at Overweight, Cites GLP-1 Drug Candidate
Structure Therapeutics Price Target Announced at $65.00/Share by JP Morgan
Structure Therapeutics Price Target Announced at $65.00/Share by JP Morgan
JPMorgan Starts Structure Therapeutics With Overweight Rating
Structure Therapeutics (GPCR) has an average rating of buy and price targets ranging from $48 to $93, according to analysts polled by Capital IQ.
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), 4D Molecular Therapeutics (FDMT) and Sanofi (OtherSNYNF)
Comments
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
7
2
$Ventyx Biosciences(VTYX.US$ $NIO Inc(NIO.US$ $Eli Lilly and Co(LLY.US$ $Structure Therapeutics(GPCR.US$
Obesity Drug - Update & Battle for Skinny
SubQ- $VKTX ph2 results puts the company in driver's seat after showing impressive results both in efficacy and safety
$VKTX has shown twice as much weight loss in 13 weeks what $LLY has done in 12 weeks and what $NVO has shown in 40 plus weeks
In safety, VKTX shown its superiority too vs LLY and NVO
For comparison...
Obesity Drug - Update & Battle for Skinny
SubQ- $VKTX ph2 results puts the company in driver's seat after showing impressive results both in efficacy and safety
$VKTX has shown twice as much weight loss in 13 weeks what $LLY has done in 12 weeks and what $NVO has shown in 40 plus weeks
In safety, VKTX shown its superiority too vs LLY and NVO
For comparison...
$Viking Therapeutics(VKTX.US$ $Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$ $Amgen(AMGN.US$ $Structure Therapeutics(GPCR.US$
Demand is too high for the obesity drugs but major drug companies unable to keep up with this demand. This will be an opportunity for multiple drug companies to take a pie out of the obesity market.
SubQ likely to be prescribed first for short term weight loss and oral drugs for maintenance. This is not an oncology space ...
Demand is too high for the obesity drugs but major drug companies unable to keep up with this demand. This will be an opportunity for multiple drug companies to take a pie out of the obesity market.
SubQ likely to be prescribed first for short term weight loss and oral drugs for maintenance. This is not an oncology space ...
9
3
$Structure Therapeutics(GPCR.US$
This stock seems to be looked past but these analysis have HIGH expectations. I think ill be entering soon. NFA
This stock seems to be looked past but these analysis have HIGH expectations. I think ill be entering soon. NFA
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.